Cannabidiol: An Overview of Some Pharmacological Aspects

@article{Mechoulam2002CannabidiolAO,
  title={Cannabidiol: An Overview of Some Pharmacological Aspects},
  author={Raphael Mechoulam and Linda A. Parker and Ruth Gallily},
  journal={The Journal of Clinical Pharmacology},
  year={2002},
  volume={42}
}
Over the past few years, considerable attention has focused on cannabidiol (CBD), a major nonpsychotropic constituent of cannabis. The authors present a review on the chemistry of CBD and discuss the anticonvulsive, antianxiety, antipsychotic, antinausea, and antirheumatoid arthritic properties of CBD. CBD does not bind to the known cannabinoid receptors, and its mechanism of action is yet unknown. It is possible that, in part at least, its effects are due to its recently discovered inhibition… Expand
Cannabidiol – Recent Advances
The aim of this review is to present some of the recent publications on cannabidiol (CBD; 2), a major non‐psychoactive constituent of Cannabis, and to give a general overview. Special emphasis isExpand
The development of Cannabidiol as a psychiatric therapeutic: a review of its antipsychotic efficacy and possible underlying pharmacodynamic mechanisms
Cannabidiol (CBD), a once-considered inert cannabis constituent, is one of two primary constituents of cannabis, alongside delta-9-tetrahydrocannabinol (?9-THC/THC). In the last 30 years, CBD hasExpand
Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice
TLDR
The effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation is investigated. Expand
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.
  • A. Zuardi
  • Psychology, Medicine
  • Revista brasileira de psiquiatria
  • 2008
TLDR
In the last 45 years it has been possible to demonstrate that CBD has a wide range of pharmacological effects, many of which being of great therapeutic interest, but still waiting to be confirmed by clinical trials. Expand
Fluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects
TLDR
A synthesis of 3 fluorinated CBD derivatives is reported, one of which, 4'-F-CBD (HUF-101) (1), is considerably more potent than CBD in behavioral assays in mice predictive of anxiolytic, antidepressant, antipsychotic and anti-compulsive activity. Expand
New cannabidiol derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their antiinflammatory activity.
TLDR
Surprisingly, it is found that hydrogenated CBD and CBD-DMH exhibit good binding to the cannabinoid receptor (CB(1), and demonstrate bioactivities different from their original compounds. Expand
Endocannabinoids and Monoamines: Modulating the Modulators
TLDR
An overview of the endocannabinoid system, a summary of current cannabinoid receptor nomenclature, and pharmacological principles as well as electrophysiological, biochemical, and behavioral evidence for cannabinoid modulation of dopaminergic, noradrenergic, and serotonergic circuitry are covered. Expand
The cannabinoid system and its pharmacological manipulation – a review, with emphasis upon the uptake and hydrolysis of anandamide
  • C. Fowler
  • Biology, Medicine
  • Fundamental & clinical pharmacology
  • 2006
TLDR
The cannabinoid system is described, with particular emphasis on the mechanisms of removal and metabolism of the endocannabinoid signalling molecule anandamide, and molecules selectively inhibiting this enzyme have potential therapeutic utility in a number of areas. Expand
Considerations and Implications of Cannabidiol Use During Pregnancy
TLDR
Despite CBD’s accessibility, there are limited studies showing its safety during pregnancy, and the use of CBD during pregnancy thus far has limited literature. Expand
Molecular Targets of Cannabidiol in Experimental Models of Neurological Disease
TLDR
Cannabidiol, through multi-target mechanisms, represents a valid therapeutic tool for the management of epilepsy, Alzheimer's disease, multiple sclerosis and Parkinson’s disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 113 REFERENCES
Cannabidiol: an overview of some chemical and pharmacological aspects. Part I: chemical aspects.
TLDR
This review presents a condensed survey of the chemistry of CBD and presents evidence that it is conceivable that, in part at least, its effects are due to its recently discovered inhibition of anandamide uptake and hydrolysis and to its anti-oxidative effect. Expand
THE ANTIEPILEPTIC POTENTIAL OF THE CANNABINOIDS
The anticonvulsant activity of marihuana and some of its surrogates was first described by Loewe and Goodman in 1947; however, detailed studies of the anticonvulsant activity of the cannabinoids wereExpand
Cannabidiol, a non‐psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats
TLDR
Cannabidiol, a major non‐psychoactive cannabinoid found in marijuana and its synthetic dimethylheptyl homolog interfere with nausea elicited by lithium chloride and with conditioned nausea eliciting by a flavor paired with lithium chloride, suggesting that cannabinoids without psychoactive side‐effects may have therapeutic value in the treatment of chemotherapy‐induced nausea. Expand
Brain Cannabinoid Systems as Targets for the Therapy of Neurological Disorders
TLDR
These endogenous structures and chemicals and mechanisms are potentially new pathophysiologic substrates, and targets for novel cannabinoid treatments, of several neurological disorders. Expand
Analgesic and antiinflammatory activity of constituents ofCannabis sativa L.
TLDR
The fact that δ1-THC and CBN were the least effective in this test suggests a structural relationship between analgesic activity and antiin-flammatory activity among the cannabinoids related to their peripheral actions and separate from the central effects of δ 1-THCs. Expand
Assessment of the role of CB1 receptors in cannabinoid anticonvulsant effects.
TLDR
A role for the cannabinoid CB1 receptor in modulating seizure activity in a whole animal model is established and it is established that the anticonvulsant effects of delta9-tetrahydrocannabinol and WIN 55,212-2 are cannabinoid CB 1 receptor-mediated while the anticoagulant activity of cannabidiol is not. Expand
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide
TLDR
Results suggest that VR1 receptors, or increased levels of endogenous AEA, might mediate some of the pharmacological effects of CBD and its analogues, and (−)‐5′‐DMH‐CBD represents a valuable candidate for further investigation as inhibitor of AEA uptake and a possible new therapeutic agent. Expand
Anticonvulsant effects of the (-) and (+)isomers of cannabidiol and their dimethylheptyl homologs.
TLDR
The anticonvulsant actions of the (-) and (+)isomers of cannabidiol and dimethylheptyl-cannabidiola were studied with the maximal electroconvulsive shock model in mice with results that potentiated pentobarbitone sleeping time and possible mechanisms of actions on receptors or membranes are discussed. Expand
Cannabinoid receptors and immunity.
TLDR
Evidence that cannabinoids modulate immunity and that cannabinoid receptors and endogenous ligands are expressed in immune tissues are reviewed. Expand
Hypnoticlike effects of cannabidiol in the rat
  • J. Monti
  • Psychology, Medicine
  • Psychopharmacology
  • 2004
TLDR
Tolerance developed to all the effects of cannabidiol on the sleep-wakefulness cycle of male Wistar rats after once-daily injections of 40 mg/kg CBD for 15 days. Expand
...
1
2
3
4
5
...